- Home
- RNXT vs ACCS Comparison
RNXT vs ACCS Comparison
Compare RNXT & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | ACCS |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 38.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | ACCS |
|---|---|---|
| Price | $0.90 | $9.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.75 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 350.4K | 26.7K |
| Earning Date | 11-13-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $928,000.00 | ★ $22,646,000.00 |
| Revenue This Year | $2,795.35 | $0.18 |
| Revenue Next Year | $272.69 | $7.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.30 |
| 52 Week Low | $0.70 | $7.72 |
| 52 Week High | $1.50 | $13.35 |
Technical Indicators
Market Signals| Indicator | RNXT | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 50.25 |
| Support Level | $0.97 | $9.25 |
| Resistance Level | $1.04 | $9.99 |
| Average True Range (ATR) | 0.08 | 0.71 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 2.86 | 19.65 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.